In modern surgical practice, efficient bleeding control remains one of the most crucial determinants of patient outcomes. Excessive intraoperative blood loss not only complicates surgical visibility but also increases postoperative complications, transfusion requirements, and recovery time. Over the last decade, hemostatic agents have evolved from simple physical barriers into advanced bioactive solutions that accelerate natural coagulation processes - effectively transforming how surgeons manage bleeding in complex procedures.
The Global Rise of Hemostatic Agents
The global market for absorbable hemostatic agents has been experiencing consistent growth. Market size is projected to rise from approximately $2.74 billion in 2024 to over $3.91 billion by 2032, with an average annual growth rate of around 4.8%. driven by an aging population, an increase in surgical volume, and innovations in biomaterial science.
These agents are now standard tools in cardiovascular, orthopedic, thoracic, and hepatobiliary surgeries - where fast and effective hemostasis can significantly reduce surgical time and postoperative complications.
Understanding Hemostatic Agents: Mechanism and Classification
Hemostatic agents can be broadly classified into mechanical, biological, and synthetic polymer-based types:
Mechanical agents (e.g., gelatin sponges, oxidized cellulose) act as scaffolds for clot formation.
Biological agents use active components like thrombin or fibrin to trigger coagulation directly.
Synthetic and plant-based polysaccharide agents, such as Surgiclean® MPH Absorbable Hemostatic Particles, utilize biocompatible starch microspheres that accelerate natural clotting without animal-derived components.
These advanced materials not only offer faster hemostasis but also minimize risks of immunogenic reactions and disease transmission.
Clinical Evidence: Speed and Efficacy Matter
Clinical comparison studies have demonstrated that modern polysaccharide-based hemostatic agents outperform traditional materials in both speed and safety:
| Parameter | Surgiclean® MPH | Axxx Brand | Gelatin Sponge |
|---|---|---|---|
| Composition | 100% Potato Starch | Potato starch | Gelatin (animal-derived) |
| Average Hemostasis Time | 1 minute | 2–3 minutes | 4–6 minutes |
| Clot Strength | 2–3× stronger than physiological clot | 1–1.5× | 1× |
| Biocompatibility | Excellent, thrombin-free | Good | Moderate (allergy risk) |
In comparative tests, Surgiclean® achieved a 1-minute hemostasis success rate significantly higher than other hemostats, particularly in complex bleeding environments such as vascular anastomosis and tumor bed resections. This superior efficacy results from its micro-network particle structure (30.8–97 μm), which rapidly absorbs plasma and concentrates platelets and coagulation factors at the bleeding site - triggering a robust endogenous clotting cascade.
The Surgiclean® Advantage: From Laboratory to Operating Room
Developed with patented reverse-phase emulsification cross-linking technology, Surgiclean® MPH Absorbable Hemostatic Particles are designed for maximum performance and safety in a wide range of surgical settings.
1. Rapid and Reliable Hemostasis
Initiates clotting within seconds upon contact, regardless of the patient's coagulation status.
Achieves complete hemostasis typically within 1 minute, effectively reducing intraoperative bleeding and postoperative drainage.
2. Safe and Biocompatible
Composed of 100% plant-derived starch; thrombin-free and non-pyrogenic.
Fully metabolized into water and CO₂ within 14 days, ensuring no residue or foreign body reaction.
Over 810,000 clinical uses with zero reported adverse events, demonstrating exceptional safety.
3. Easy to Use
No mixing or refrigeration required - simply open and apply directly.
Available in multiple specifications (0.5g–5g) and applicator options (TQ-1 to TQ-4) for both open and laparoscopic surgeries.
Ideal for hard-to-reach or diffuse bleeding areas where ligation or electrocautery is ineffective.
4. Environmentally Sustainable
As a biodegradable, plant-based product, Surgiclean® supports greener surgical practices by avoiding animal-derived ingredients and minimizing post-surgical waste. Learn more about our commitment to safe and sustainable surgical materials at Surgiclean.net.
Clinical Applications Across Specialties
Surgiclean® MPH is widely used across a variety of procedures:
Cardiovascular Surgery: Controls oozing at vascular anastomosis during coronary artery bypass grafting and aneurysm repair.
Thoracic Surgery: Reduces air leaks and bleeding in lung cancer resections and lymph node dissections.
Hepatobiliary and Pancreatic Surgery: Effective on liver resection wounds and pancreatic parenchymal surfaces, minimizing postoperative drainage.
Thyroid and Breast Surgery: Decreases oozing near delicate structures like the recurrent laryngeal nerve, reducing postoperative drainage and recovery time.
Orthopedic and Trauma Surgery: Ensures rapid hemostasis on bone and soft tissue wounds, improving surgical field visibility and reducing transfusion rates.
Its broad compatibility with both open and minimally invasive procedures gives surgeons flexibility and confidence in complex cases.
Why Distributors and Clinics Choose Surgiclean®
For distributors, Surgiclean® offers a strong market opportunity in the fast-growing segment of absorbable hemostatic agents. Its proven safety, clinical performance, and wide surgical applicability make it ideal for hospital procurement and medical supply distribution.
For surgical teams, it provides a ready-to-use, reliable, and cost-effective alternative to animal-derived hemostatic agents - improving both operational efficiency and patient safety.